Non-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study
Non-invasive Diagnosis of Coronary Microvascular Disease Using Novel CMR and CT Techniques: a Pilot Study
University of Leicester
20 participants
Nov 1, 2023
OBSERVATIONAL
Conditions
Summary
* 40% of patients presenting with stable chest pain (angina) have no significant blockage of the main heart arteries. Identifying why these patients have symptoms will mean better treatment options can be developed. * About 60% of these patients have evidence of coronary microvascular disease (CMD). In this condition there is a problem with the heart's microvessels (very small blood vessels that branch from the main heart arteries). Due to problems with these vessels there is a mismatch between the blood supply to the heart and its oxygen consumption, causing chest pain and this can also lead to major heart events. * At present, to diagnose this condition, specialised techniques during an invasive test, called a coronary angiogram, are required. As this is an invasive test, it can be lead to complications and cause discomfort. * Non-invasive ways of diagnosing CMD are required to improve the diagnosis and management of this condition. * This study aims to provide initial data on whether novel imaging techniques using CT and MRI scans, which are much less invasive, could identify CMD. * To do this, patients with suspected angina referred for angiography and who are already participants in the main research study 'CMR versus CT-FFR in CAD' study will be recruited. * These will be patients with suspected CMD and also those with blockage of the main heart arteries (triple vessel disease) to compare against. * Participants in this pilot study will have additional tests used to diagnose CMD during their invasive angiography procedure. Participants will then have an MRI scan involving novel techniques and exercise MRI, where individuals exercise use a cycle or stepping machine during the MRI scan. Further analysis will also be undertaken of CT images acquired as part of the main study. * These tests will be compared against invasive test results to see which show potential in being able to diagnose CMD.
Eligibility
Inclusion Criteria13
- Current participant of the 'CMR versus CT-FFR in CAD' study
- Patients aged ≥18 years
- Referred for invasive coronary angiography for investigation of chest pain
- Willing and able to give informed consent
- Willing and able (in the Investigators opinion) to comply with all study requirements.
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
- Able to understand written English
- Able to perform exercise in the MRI scanner
- Study arm:
- No evidence of obstructive or non-obstructive CAD on research CTCA
- Myocardial perfusion defect detected on adenosine stress CMR indicative of CMD
- Control arm:
- • Evidence of multivessel CAD on research CTCA
Exclusion Criteria11
- Recent acute coronary syndrome (\< 6 months)
- Severe claustrophobia
- Absolute contraindications to CMR - those with MR conditional or safe devices will be included
- Second-/third-degree atrioventricular block
- Severe chronic obstructive pulmonary disease
- Moderate-severe asthma
- Estimated glomerular filtration rate \<30 ml/min/1.73m2
- Women who are pregnant, breast-feeding or of child-bearing potential (premenopausal women)
- Contraindication to iodinated contrast
- Participants who have participated in a research study involving an investigational product in the past 12 weeks
- Patients unable to understand written English
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
During invasive coronary angiography, in addition to coronary angiography performed as per routine clinical care, participants will have angiographic testing for coronary microvascular disease using routine clinical procedures. This will consist of fractional flow reserve (FFR), coronary flow reserve, index of microvascular resistance and vasospasm provocation testing with acetylcholine (Ach).
Participants will undergo a cardiac magnetic resonance scan compromising 1) T1 mapping, 2) oxygenation-sensitive MRI and 3) perfusion imaging. All will be obtained at rest and during exercise using a step ergometer.
Previously acquired CTCA images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06070662